Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
P Dorian, T Kongnakorn, H Phatak… - European heart …, 2014 - academic.oup.com
Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands
J Stevanović, M Pompen, HH Le, MH Rozenbaum… - PLoS …, 2014 - journals.plos.org
Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation
S Lee, R Mullin, J Blazawski, CI Coleman - 2012 - journals.plos.org
Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …
Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin
S Lee, MW Anglade, J Meng, K Hagstrom… - … Quality and Outcomes, 2012 - Am Heart Assoc
Background—Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF)
patients unsuitable for warfarin by 63% but does not increase major bleeding. We sought to …
patients unsuitable for warfarin by 63% but does not increase major bleeding. We sought to …
[HTML][HTML] Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation
T Lanitis, T Kongnakorn, L Jacobson, A De Geer - Thrombosis research, 2014 - Elsevier
Introduction Atrial fibrillation (AF), one of the major risk factors for stroke, imposing a
substantial burden to the Swedish health care system. Apixaban has demonstrated …
substantial burden to the Swedish health care system. Apixaban has demonstrated …
[HTML][HTML] Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation
Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …
Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
AS Hersi, KM Osenenko, SA Kherraf… - Annals of Saudi …, 2019 - annsaudimed.net
ABSTRACT BACKGROUND: Apixaban, an oral anticoagulant for stroke and systemic
embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in …
embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in …
A systematic literature review on the cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation
C Pinyol, JM Cepeda, I Roldan, V Roldan… - Cardiology and …, 2016 - Springer
Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …
economic resources, the expense of many new treatments, the need to allocate health …
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
RD Lopes, JH Alexander, SM Al-Khatib, J Ansell… - American heart …, 2010 - Elsevier
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …
[HTML][HTML] Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan
I Kamae, Y Hashimoto, Y Koretsune, N Tanahashi… - Clinical …, 2015 - Elsevier
Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …
相关搜索
- cost effectiveness stroke prevention
- atrial fibrillation stroke prevention
- cost effectiveness atrial fibrillation
- safety of apixaban stroke prevention
- atrial fibrillation apixaban for reduction
- warfarin and aspirin stroke prevention
- atrial fibrillation warfarin and aspirin
- economic evaluation apixaban for the prevention
- cost effectiveness warfarin and aspirin
- atrial fibrillation efficacy and safety
- atrial fibrillation design and rationale
- atrial fibrillation reduction in stroke
- atrial fibrillation safety of apixaban
- economic evaluation prevention of stroke
- efficacy and safety stroke prevention